Suppr超能文献

一项关于 Dilapan-S 与 Foley 球囊用于引产前宫颈成熟的随机对照试验(DILAFOL 试验)。

A randomized controlled trial of Dilapan-S vs Foley balloon for preinduction cervical ripening (DILAFOL trial).

机构信息

Department of Obstetrics and Gynecology, University of Texas Medical Branch at Galveston, Galveston, TX.

Department of Obstetrics and Gynecology, University of Texas Medical Branch at Galveston, Galveston, TX.

出版信息

Am J Obstet Gynecol. 2019 Mar;220(3):275.e1-275.e9. doi: 10.1016/j.ajog.2019.01.008. Epub 2019 Feb 18.

Abstract

OBJECTIVE

The objective of the study was to test the hypothesis that Dilapan-S is not inferior to the Foley balloon for preinduction cervical ripening at term.

STUDY DESIGN

Pregnant women ≥37 weeks scheduled for induction with unfavorable cervix (≤3 cm dilated and ≤60% effaced) were randomly assigned to 12 hours of either Foley balloon inflated with 60 mL saline or Dilapan-S for cervical ripening. If the cervix remained unfavorable, then 1 more round of the assigned dilator was used. Management following ripening was left up to the clinical providers. The primary outcome was vaginal delivery. A satisfaction survey was also obtained after the preinduction period. Sample size was based on a noninferiority margin of 10%, 90% power, and an estimated frequency of vaginal delivery of 71% in Foley balloon and 76% in Dilapan-S.

RESULTS

From November 2016 through February 2018, 419 women were randomized (209 to Foley balloon; 210 to Dilapan-S). In the intent-to-treat analysis, vaginal delivery was more common in Dilapan-S vs Foley balloon (81.3% vs 76.1%), with an absolute difference with respect to the Foley balloon of 5.2% (95% confidence interval, -2.7% to 13.0%) indicating noninferiority for the prespecified margin. The difference was not large enough to show superiority. Noninferiority was confirmed in the per-protocol population (n = 204 in the Foley balloon, n = 188 in Dilapan-S), supporting the robustness of the results. Secondary outcomes were not different between groups, except for a longer time the device remained in place in Dilapan-S compared with the Foley balloon. Maternal and neonatal adverse events were not significantly different between groups. A priori interaction analyses showed no difference in the effect on vaginal delivery by cervical dilation at randomization, parity, or body mass index >30 kg/m. Patients with Dilapan-S were more satisfied than patients with the Foley balloon as far as sleep (P = .01), relaxing time (P = .001), and performance of desired daily activities (P = .001).

CONCLUSION

Dilapan-S is not inferior to the Foley balloon for preinduction cervical ripening at term. Advantages of Dilapan-S over Foley include Food and Drug Administration approval, safe profile, no protrusion from the introitus, no need to keep under tension, and better patient satisfaction.

摘要

目的

本研究旨在验证以下假设,即与 Foley 球囊相比,Dilapan-S 在足月引产时用于宫颈成熟并不差。

研究设计

选择≥37 周、宫颈不成熟(扩张<3cm,<60%展平)拟行引产的孕妇,随机分为 Foley 球囊组(生理盐水 60mL 充盈)或 Dilapan-S 组 12 小时,用于宫颈成熟。如果宫颈仍不成熟,可再使用一轮指定的扩张器。成熟后处理方法由临床医生决定。主要结局是阴道分娩。诱导前还进行了满意度调查。样本量基于非劣效性边界 10%、90%效能和 Foley 球囊估计的阴道分娩率 71%、Dilapan-S 为 76%。

结果

2016 年 11 月至 2018 年 2 月,419 名孕妇随机分组(Foley 球囊组 209 例,Dilapan-S 组 210 例)。意向治疗分析显示,Dilapan-S 组阴道分娩率高于 Foley 球囊组(81.3% vs 76.1%),Foley 球囊组的绝对差异为 5.2%(95%置信区间,-2.7%至 13.0%),表明符合预设边界的非劣效性。但差异不足以显示优越性。在方案人群(Foley 球囊组 204 例,Dilapan-S 组 188 例)中也证实了非劣效性,支持结果的稳健性。次要结局在两组间无差异,除了 Dilapan-S 组的设备保留时间长于 Foley 球囊组。两组间的母婴不良事件无显著差异。预先进行的交互分析显示,随机化时宫颈扩张、产次或 BMI>30kg/m2 对阴道分娩的影响无差异。与 Foley 球囊组相比,Dilapan-S 组的患者在睡眠(P=0.01)、放松时间(P=0.001)和日常活动表现(P=0.001)方面的满意度更高。

结论

与 Foley 球囊相比,Dilapan-S 在足月引产时用于宫颈成熟并不差。与 Foley 球囊相比,Dilapan-S 的优势在于获得美国食品和药物管理局批准、安全性好、不会从阴道突出、无需保持张力、患者满意度更高。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验